Literature DB >> 1331419

Comparative in vivo and in vitro regional selectivity of central omega (benzodiazepine) site ligands in inhibiting [3H]flumazenil binding in the rat central nervous system.

J Benavides1, B Peny, A Durand, S Arbilla, B Scatton.   

Abstract

The in vivo selectivity for central omega (benzodiazepine) modulatory site subtypes of ligands from several chemical classes has been evaluated by measuring the displacement of the in vivo binding of [3H]flumazenil to several rat central nervous system structures differentially enriched in omega 1 and omega 2 sites. This labeling was prevented in a dose-related manner by the i.p. administration, 30 min before the radioligand, of several benzodiazepine derivatives, the cyclopyrrolone derivatives suriclone and zopiclone, the triazolopyridazine derivative CL 218,872 and the imidazopyridine derivative zolpidem. Most of the benzodiazepine derivatives studied displayed in vivo some selectivity for omega 2-enriched structures. In contrast, oxoquazepam and CL 218,872 were 2- to 3-fold more potent at preventing [3H]flumazenil binding in omega 1-enriched (cerebellum) than in omega 2-enriched structures. Maximal inhibitions by zolpidem of in vivo [3H]flumazenil binding [cerebellum (100%) > cerebral cortex (79%) > or = striatum (74%) > hippocampus (52%) > spinal cord (37%)] were related to the relative omega 1/omega 2 distribution ratio in each structure. These differences did not result from an uneven distribution of this compound in the central nervous system. Quantitative autoradiographic studies performed on 30 central nervous system regions showed a strong correlation between the in vitro and in vivo regional selectivity of zolpidem. For all the drugs studied there was a significant global correlation between their potency at inhibiting [3H]flumazenil binding in vitro and in vivo either in the cerebellum (P < .001) or in the spinal cord (P < .01) and between the in vitro and in vivo cerebellum/spinal cord selectivity. The differential in vivo selectivity of zolpidem may account for the reported hypnoselective profile of this imidazopyridine in the rodent.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1331419

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

1.  Selective labelling of diazepam-insensitive GABAA receptors in vivo using [3H]Ro 15-4513.

Authors:  Luanda J Pym; Susan M Cook; Thomas Rosahl; Ruth M McKernan; John R Atack
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

2.  Tolerance, cross-tolerance and dependence measured by operant responding in rats treated with triazolam via osmotic pumps.

Authors:  C Cohen; D J Sanger
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

3.  Effects of eszopiclone and zolpidem on sleep-wake behavior, anxiety-like behavior and contextual memory in rats.

Authors:  Max P Huang; Kushan Radadia; Brian W Macone; Sanford H Auerbach; Subimal Datta
Journal:  Behav Brain Res       Date:  2010-02-12       Impact factor: 3.332

4.  The role of α1 and α5 subunit-containing GABAA receptors in motor impairment induced by benzodiazepines in rats.

Authors:  Marija Milić; Jovana Divljaković; Sundari Rallapalli; Michael L van Linn; Tamara Timić; James M Cook; Miroslav M Savić
Journal:  Behav Pharmacol       Date:  2012-04       Impact factor: 2.293

5.  Discriminative stimulus effects of omega (BZ) receptor ligands: correlation with in vivo inhibition of [3H]-flumazenil binding in different regions of the rat central nervous system.

Authors:  D J Sanger; J Benavides
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Effects of benzodiazepine receptor ligands on the performance of an operant delayed matching to position task in rats: opposite effects of FG 7142 and lorazepam.

Authors:  B J Cole; M Hillmann
Journal:  Psychopharmacology (Berl)       Date:  1994-07       Impact factor: 4.530

Review 7.  The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents.

Authors:  David J Sanger
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Benzodiazepine-induced intestinal motor disturbances in rats: mediation by omega 2 (BZ2) sites on capsaicin-sensitive afferent neurones.

Authors:  C Bonnafous; B Scatton; L Buéno
Journal:  Br J Pharmacol       Date:  1994-09       Impact factor: 8.739

9.  Effects of benzodiazepine receptor partial inverse agonists in the elevated plus maze test of anxiety in the rat.

Authors:  B J Cole; M Hillmann; D Seidelmann; M Klewer; G H Jones
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

10.  Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.

Authors:  Susan M Hanson; Elaine V Morlock; Kenneth A Satyshur; Cynthia Czajkowski
Journal:  J Med Chem       Date:  2008-11-27       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.